Personal insulin pumps, continuous glucose-monitoring systems (CGMSs), and, most recently, hybrid closed-loop (HCL) systems, which are characterized by the coexistence of algorithm-driven automated insulin delivery combined with manual mealtime boluses, have had a major effect on the management of type 1 diabetes mellitus (T1DM) [2]. This evidence concerns the gene INS and type 1 diabetes mellitus.